Vimta Labs Limited (VIMTALABS) AI Stock Analysis

• Market Cap: ₹27.11B
• Dividend Yield: 0.16%
• Average Volume (3M): 801.34K
• Price to Earnings (P/E): 36.6
• Beta (1Y): 0.73
• Revenue Growth: 15.84%
• EPS Growth: 79.69%
• Country: IN
• Employees: 1,428
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 4.25
• Shares Outstanding: 44,505,570
• 10 Day Avg. Volume: 1,186,551
• 30 Day Avg. Volume: 801,343
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹731.00
• Price Target Upside: 19.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 72 Outperform
• Price Target: ₹731.00 ▲(19.99% Upside)

Vimta Labs Limited's strong financial performance is the main strength, supported by healthy revenue growth, solid profitability, and a robust balance sheet. The stock's bullish technical indicators are tempered by overbought signals, while the high P/E ratio suggests a premium valuation. The lack of data from the earnings call and notable corporate events did not impact the score.

Vimta Labs Limited Business Overview & Revenue Model

Company Description

Vimta Labs Limited is a leading contract research and testing organization based in India, providing a comprehensive range of services across various industries including pharmaceuticals, biotechnology, food, agriculture, and environmental sectors. The company's core services encompass analytical testing, clinical research, environmental monitoring, and food safety assessments, catering to both national and international clients.

How the Company Makes Money

Vimta Labs Limited generates revenue through a diversified portfolio of services offered to its clientele. The primary revenue streams include analytical testing services for pharmaceuticals and biotechnology companies, which involve testing drug substances, drug products, and biological samples. Another significant revenue stream is clinical research services, including bioavailability and bioequivalence studies essential for drug development. The company also derives income from environmental testing and monitoring services, food and agriculture testing, which ensures compliance with safety and quality standards. Additionally, Vimta Labs benefits from long-term partnerships and contracts with major corporations and government agencies, contributing to a steady revenue flow.

Vimta Labs Limited Financial Statement Overview

Summary

Vimta Labs Limited exhibits strong financial health with consistent revenue growth and solid profitability metrics. The balance sheet reflects low leverage and high equity, enhancing financial stability. Cash flows are improving, but there is potential for further strengthening free cash flow.

Income Statement

Vimta Labs Limited demonstrates strong financial performance with consistent revenue growth, achieving a notable 8.07% increase from 2024 to 2025. The company maintains a robust gross profit margin averaging around 40.76% in 2025, while net profit margin has improved significantly to 19.58% in the same year. The EBIT margin of 25.20% and a strong EBITDA margin of 36.69% indicate efficient operations and cost management.

Balance Sheet

The balance sheet remains solid with a low debt-to-equity ratio of 0.02, reflecting conservative leverage. Return on equity is strong at 17.77%, demonstrating effective use of shareholder capital. The equity ratio stands at an impressive 81.19%, highlighting financial stability and a strong asset base.

Cash Flow

Cash flow analysis reveals positive trends with free cash flow improving from negative in 2024 to positive in 2025. Operating cash flow to net income ratio is healthy at 1.41, indicating strong cash generation relative to net earnings. However, free cash flow to net income ratio remains relatively modest, suggesting room for improvement in cash retention.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.51B	3.44B	3.18B	3.15B	2.76B	2.09B
Gross Profit	2.39B	1.33B	2.42B	2.41B	1.97B	1.47B
EBITDA	1.25B	1.26B	902.01M	966.38M	798.44M	533.46M
Net Income	691.10M	673.42M	410.09M	481.72M	413.30M	214.05M
Balance Sheet
Total Assets	4.67B	4.67B	4.00B	3.62B	3.07B	2.74B
Cash, Cash Equivalents and Short-Term Investments	327.21M	327.21M	256.01M	395.73M	112.06M	65.85M
Total Debt	85.15M	85.15M	191.89M	149.88M	193.41M	304.15M
Total Liabilities	876.84M	876.84M	803.54M	805.39M	732.14M	799.75M
Stockholders Equity	3.79B	3.79B	3.20B	2.82B	2.34B	1.94B
Cash Flow
Free Cash Flow	0.00	157.66M	-156.78M	381.32M	203.45M	40.93M
Operating Cash Flow	0.00	948.30M	608.92M	879.37M	590.69M	371.82M
Investing Cash Flow	0.00	-755.37M	-760.48M	-572.56M	-378.48M	-319.24M
Financing Cash Flow	0.00	-166.81M	-19.03M	-109.81M	-166.14M	-45.70M

Vimta Labs Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 609.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIMTALABS, the sentiment is Positive. The current price of 609.2 is above the 20-day moving average (MA) of 591.09, above the 50-day MA of 518.68, and above the 200-day MA of 473.51, indicating a bullish trend. The MACD of 42.18 indicates Positive momentum. The RSI at 57.20 is Neutral, neither overbought nor oversold. The STOCH value of 29.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VIMTALABS.

Vimta Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIMTALABS	72 Outperform	₹27.11B	36.58		0.16%	15.84%	79.69%
SAKAR	68 Neutral	₹7.26B	36.27		―	21.65%	73.84%
Sector *	64 Neutral	CHF26.61B	17.29	9.71%	2.35%	21.08%	2.84%
KRSNAA	63 Neutral	₹26.05B	32.35		0.31%	13.78%	32.19%
SMSPHARMA	61 Neutral	₹20.42B	26.99		0.18%	10.29%	26.79%
SOLARA	53 Neutral	₹29.08B	126.42		―	-7.29%	―
INDOCO	47 Neutral	₹26.90B	96.22		0.53%	-8.28%	-247.34%

Vimta Labs Limited Corporate Events

Vimta Labs’ Credit Ratings Reaffirmed, Reflecting Strong Industry Position

Vimta Labs Limited announced that CARE Ratings Limited has reaffirmed its credit ratings for various bank facilities, reflecting the company’s strong position in the CRT industry. The reaffirmation is supported by Vimta’s diversified revenue base, strong financial performance, and strategic divestment of low-margin businesses. However, the company faces challenges due to its moderate scale of operations and exposure to regulatory risks. The stable outlook considers the completion of lab space construction, which is expected to support growth and maintain healthy profitability margins.